ArticleOncogene2011
Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis.
Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Construction and analysis of multiparameter prognostic models for melanoma outcome.Methods in molecular biology (Clifton, N.J.) · 2014Pooled it
- Article
- Article
- BRMS1: a multifunctional signaling molecule in metastasis.Cancer metastasis reviews · 2020Review
- Cell cycle regulatory markers in melanoma: New strategies in diagnosis and treatment.Medical journal of the Islamic Republic of Iran · 2019Review
- Article
- Genetics of metastasis: melanoma and other cancers.Clinical & experimental metastasis · 2018Review
- BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018Article
- Scinderin is a novel transcriptional target of BRMS1 involved in regulation of hepatocellular carcinoma cell apoptosis.American journal of cancer research · 2018Article
- Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma.Oncotarget · 2017Article
- KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.Oncotarget · 2016Article
- Cullin3 promotes breast cancer cells metastasis and epithelial-mesenchymal transition by targeting BRMS1 for degradation.Oncotarget · 2015Article
- Hypoxia-independent drivers of melanoma angiogenesis.Frontiers in oncology · 2015Review
- Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.Molecular and cellular biology · 2015Article
- Down-regulation of BRMS1 by DNA hypermethylation and its association with metastatic progression in triple-negative breast cancer.International journal of clinical and experimental pathology · 2015Article
- Expression of the metastasis suppressor BRMS1 in uveal melanoma.Ecancermedicalscience · 2014Article
- BRMS1 suppresses glioma progression by regulating invasion, migration and adhesion of glioma cells.PloS one · 2014Article
- Modelling and simulation of mutant alleles of breast cancer metastasis suppressor 1 (BRMS1) gene.Bioinformation · 2014Article
- Expression and prognostic significance of a new tumor metastasis suppressor gene LASS2 in human bladder carcinoma.Medical oncology (Northwood, London, England) · 2012Article
- Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival.BMC cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Breast cancer metastasis suppressor 1 (BRMS1) has been reported to suppress metastasis without significantly affecting tumorigenicity in breast cancer and ovarian cancer. To investigate the role of BRMS1 in human melanoma progression and prognosis, we established tissue microarray and BRMS1 expression was evaluated by immunohistochemistry in 41 dysplastic nevi, 90 primary melanomas and 47 melanoma metastases. We found that BRMS1 expression was significantly decreased in metastatic melanoma compared with primary melanoma or dysplastic nevi (P=0.021 and 0.001, respectively, χ(2) test). In addition, reduced BRMS1 staining was significantly correlated with American Joint Committee on Cancer stages (P=0.011, χ(2) test), but not associated with tumor thickness, tumor ulceration and other clinicopathological parameters. Furthermore, BRMS1 expression was significantly correlated with disease-specific 5-year survival of melanoma patients (P=0.007, log-rank test). Multivariate Cox regression analysis revealed that BRMS1 staining was an independent prognostic factor for melanoma patients (relative risk=0.51; confidence interval=0.29-0.91; P=0.022). Moreover, we demonstrated that BRMS1 overexpression inhibited endothelial cell growth and tube formation ability by suppressing NF-κB activity and IL-6 expression in vitro. We also showed that knockdown of BRMS1 increased IL-6 expression and promoted endothelial cell growth and tube formation. In addition, our data revealed that the BRMS1-mediated IL-6 expression is dependent on NF-κB. Strikingly, our in vivo studies using nude mice confirmed that BRMS1 inhibited blood vessel formation and the recruitment of CD31-positive cells in matrigel plugs. Taken together, BRMS1 expression was decreased in metastatic melanomas, which resulted in deficient suppression of angiogenesis and contributed to melanoma progression. BRMS1 may serve an important prognostic marker and therapeutic target for melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.